Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Payables (2017 - 2025)

Entera Bio has reported Payables over the past 8 years, most recently at $448000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 239.39% year-over-year to $448000.0, compared with a TTM value of $448000.0 through Dec 2025, up 239.39%, and an annual FY2025 reading of $448000.0, up 239.39% over the prior year.
  • Payables came in at $448000.0 for Q4 2025, up from $216000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $564000.0 in Q3 2023 to a low of $17000.0 in Q4 2022.
  • Median Payables over the past 5 years was $166000.0 (2021), compared with a mean of $210176.5.
  • The sharpest move saw Payables tumbled 89.76% in 2022, then skyrocketed 455.07% in 2025.
  • Over 5 years, Payables stood at $166000.0 in 2021, then tumbled by 89.76% to $17000.0 in 2022, then surged by 388.24% to $83000.0 in 2023, then skyrocketed by 59.04% to $132000.0 in 2024, then soared by 239.39% to $448000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Payables are $448000.0 (Q4 2025), $216000.0 (Q3 2025), and $383000.0 (Q2 2025).